Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial

INTRODUCTION: Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and qualit...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaçi, Diamant, Strober, Bruce, Gordon, Kenneth B., Foley, Peter, Gooderham, Melinda, Morita, Akimichi, Papp, Kim A., Puig, Lluís, Menter, M. Alan, Colombo, Matthew J., Elbez, Yedid, Kisa, Renata M., Ye, June, Napoli, Andrew A., Wei, Lan, Banerjee, Subhashis, Merola, Joseph F., Gottlieb, Alice B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850503/
https://www.ncbi.nlm.nih.gov/pubmed/35025062
http://dx.doi.org/10.1007/s13555-021-00649-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850503/
https://www.ncbi.nlm.nih.gov/pubmed/35025062
http://dx.doi.org/10.1007/s13555-021-00649-y

Ejemplares similares